IFSUF yields 7.96% · JNJ yields 2.14%● Live data
📍 IFSUF pulled ahead of the other in Year 1
Combined, IFSUF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of IFSUF + JNJ for your $10,000?
Infrastrutture Wireless Italiane S.p.A. operates in the electronic communications infrastructure sector in Europe. The company offers infrastructure hosting equipment for radio broadcasting, telecommunications, and television, and radio signal broadcasting. It also provides integrated hosting services, including cellular communication and broadcast towers; infrastructures, such as cabling, spaces for equipment, technological plant for power supply, and air-conditioning systems for developing wireless networks, sensors, IoT, and VDS. In addition, the company offers indoor and outdoor mobile networks, such as distributed antenna systems and small cells in public administration, hospitals, airports and stations, museums, production complexes, shopping centers, retail facilities and shops, sports facilities, hotels, amusement parks, credit institutes, offices and co-working spaces, and car parks; and management, development, and backhauling services. It serves network operators; operators with licenses for radio transmission services in other wireless technologies; broadcasting service operators; and institutions, public entities, and the armed forces. The company was incorporated in 2015 and is headquartered in Milano, Italy.
Full IFSUF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.